NFA
OVID icon

Nationwide Fund Advisors’s Ovid Therapeutics OVID Stock Holding History

Nationwide Fund Advisors’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,879
Closed -$25K – 1481
2017
Q3 		$25K Hold
2,879
– – ﹤0.01% 3094
2017
Q2 		$30K Buy
+2,879
New +$37.6K ﹤0.01% 3088

Other funds holding OVID

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nationwide Fund Advisors's OVID Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Ovid Therapeutics (OVID) in Q4 2017, closing a stake of 2,879 shares — an estimated $25K sold.

Nationwide Fund Advisors first reported a position in OVID in Q2 2017 and held it in 2 quarters. The position peaked at $30K in Q2 2017. 49 funds tracked by Wall St. Rank hold OVID as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Ovid Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 2,879 Ovid Therapeutics shares in Q4 2017, an estimated $25K.
  • Nationwide Fund Advisors first reported a position in Ovid Therapeutics in Q2 2017 and held it in 2 quarters.
  • Nationwide Fund Advisors's Ovid Therapeutics position peaked at $30K in Q2 2017.
  • 49 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.